Author

N. Modhiran

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 4 Biochemistry· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Organism:human· 5 Research Focus:host-pathogen & immune response· 4 Research Focus:drug response / drug discovery· 2 Assay:proteomics· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Organism:mouse· 1

Frequent Co-Authors

D. Watterson· 6 shared A. A. Amarilla· 4 shared A. A. Khromykh· 4 shared B. Liang· 3 shared P. R. Young· 3 shared A. Isaacs· 2 shared K. Chappell· 2 shared M. Chhabra· 2 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 34 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersMicrobiology

D. Watterson

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Alternative cell entry mechanisms for SARS-CoV-2 and multiple animal viruses

R. Ojha, A. Jiang, E. Mantyla, N. Modhiran, R. Witte, A. Gaudin, L. De Zanetti, R. Gormal, M. Vihinen-Ranta, J. Mercer, M. Suomalainen, U. F. Greber, Y. Yamauchi, P. Yves-Lozach, A. Helenius, , G. Balistreri

This study identifies alternative cell entry mechanisms for SARS-CoV-2 and other viruses, showing some rely on dynamin while others use actin-dependent pathways.

bioRxiv · Jul 2, 2023 · PreprintMicrobiology

The role of N-glycosylation in spike antigenicity for the SARS-CoV-2 Gamma variant

C. L. Pegg, N. Modhiran, R. Parry, B. Liang, A. A. Amarilla, A. Khromykh, L. Burr, P. Young, K. Chappell, B. L. Schulz, D. Watterson

This study compares glycosylation and antigenicity of SARS-CoV-2 Wu-1 and Gamma variants, finding that an NTD mutation alters glycan site occupancy but not antibody binding.

bioRxiv · Apr 3, 2023 · PreprintBiochemistry

An alpaca-derived nanobody neutralizes the SARS-CoV-2 omicron variant

N. Modhiran, S. M. Lauer, A. A. Amarilla, P. Hewins, S. I. L. van den Broek, Y. S. Low, N. Thakur, B. Liang, G. V. Nieto, J. Jung, D. Paramitha, A. Isaacs, J. de Sng, D. Song, J. Jorgensen, , D. Watterson

This paper identifies a nanobody that effectively neutralizes the SARS-CoV-2 Omicron variants BA.1 and BA.2, showing high affinity and pre-clinical promise.

bioRxiv · Dec 27, 2022 · PreprintMicrobiology

SARS-CoV-2 triggers complement activation through interactions with heparan sulfate

M. W. Lo, A. A. Amarilla, J. D. Lee, E. A. Albornoz, N. Modhiran, R. J. Clark, V. Ferro, M. Chhabra, A. A. Khromykh, D. Watterson, T. M. Woodruff

This study shows SARS-CoV-2 activates the complement system via heparan sulfate interactions, leading to C5a production and delayed granulocyte/monocyte activation.

bioRxiv · Jan 11, 2022Immunology

Complete protection by a single dose skin patch delivered SARS-CoV-2 spike vaccine

C. L. D. McMillan, J. J. Y. Choo, A. Idris, A. Supramaniam, N. Modhiran, A. A. Amarilla, A. Isaacs, S. T. M. Cheung, B. Liang, H. Bielefeldt-Ohmann, A. Azuar, D. Acharya, G. Kelly, G. J. P. Fernando, M. J. Landsberg, , D. A. Muller

A single dose of a SARS-CoV-2 spike vaccine delivered via a high-density microarray patch provides complete protection against a lethal virus challenge.

bioRxiv · May 30, 2021Microbiology

Synthetic Heparan Sulfate Mimetic Pixatimod (PG545) Potently Inhibits SARS-CoV-2 By Disrupting The Spike-ACE2 interaction

S. E. Guimond, C. J. Mycroft-West, N. S. Gandhi, J. A. Tree, T. T. Le, C. M. Spalluto, M. V. Humbert, K. R. Buttigieg, N. Coombes, M. J. Elmore, K. Nystrom, J. Said, Y. X. Setoh, A. Amarilla, N. Modhiran, , J. E. Turnbull

This paper shows that pixatimod inhibits SARS-CoV-2 by disrupting the Spike-ACE2 interaction, demonstrating its potential as an anti-COVID-19 therapeutic.

bioRxiv · Jun 24, 2020Microbiology